Health Canada Approves Merck’s Keytruda As A Monotherapy To Treat MSI-H Or DMMR Solid Tumours
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Merck & Co Inc. (MRK) on Thursday said that Health Canada has granted approval of Keytruda as a monotherapy to treat patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1474708560-6c55d2b4d2b44978aa809c330165c3e5.jpg "Do I Need to File an Income Tax Return Every Year?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-89739213-33fa62bb8fd14c5b98e1ae20e7c0b58b.jpg "3 Surprising Stocks That Have Outperformed Big Names in the Last 10 Years")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1632178785-2bbf98c928b749329959617a646e8bf8.jpg "How WhatsApp Makes Money")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1132012708-0d3f8f4b04c14405aa72e54940ab6a0e-3064dc565912458a94297c60b3d609e7.jpg "Is a Career in Investment Banking Worth It?")
:max_bytes(150000):strip_icc():format(jpeg)/KraftCadburyHostileTakeover-56143341d0004032a1cdb65ec3c2859b.jpg "What Are Some Top Examples of Hostile Takeovers?")